Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Meiotic nuclear division protein 1 homolog (MND1) is a highly conserved eukaryotic protein necessary for proper homologous chromosome pairing and the resolution of meiotic double-strand breaks. In mammals, the MND1 protein forms a stable heterodimeric complex with Hop2. This complex binds both DNA and recombinase proteins (Dmc1, Rad51), stimulating their activity to drive strand invasion and cross-over events during the meiotic recombination process. Structurally, MND1 contains a winged-helix DNA-binding domain and several coiled-coil leucine zipper regions that facilitate dimerization and protein interactions. Loss of MND1 function causes severe defects in meiosis, resulting in infertility conditions such as primary ovarian insufficiency and azoospermia. MND1 is not typically regarded as a druggable therapeutic target and has limited clinical biomarker value, but is crucial for germline genome integrity.
Not applicable (no drugs are known to target MND1 directly)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Meiotic nuclear division protein 1 homolog (MND1).